Sphincterotomy for Acute Recurrent Pancreatitis
(SHARP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a procedure called ERCP with sphincterotomy can reduce the risk or frequency of pancreatitis episodes in individuals with pancreas divisum. ERCP with sphincterotomy uses an endoscope (a flexible, lighted tube) and x-rays to locate and open the pancreatic duct, improving fluid drainage. Participants will receive either this procedure or a "sham" procedure for comparison. This trial may suit those diagnosed with pancreas divisum, who have experienced at least two episodes of pancreatitis, and are eligible for the ERCP procedure. As an unphased trial, it offers a unique opportunity to contribute to understanding a potential treatment for pancreas divisum.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if your medication is identified as a cause of your pancreatitis, you may not be eligible to participate.
What prior data suggests that the ERCP with sphincterotomy procedure is safe for patients with pancreas divisum?
Research has shown that ERCP with sphincterotomy is generally safe for patients. One study found that about 7.8% of patients experienced complications soon after the procedure, with a few encountering issues later. However, most patients, approximately 94%, did not face major problems. This indicates that while some risk exists, the procedure is usually well-tolerated.
ERCP is often used to treat conditions like pancreatitis and has proven effective for many individuals. However, every medical procedure carries some risk. Participants should consult their doctors to understand the benefits and risks specific to their situation.12345Why are researchers excited about this trial?
Researchers are excited about the technique of ERCP with minor papilla endoscopic sphincterotomy (miES) for acute recurrent pancreatitis because it offers a new approach to managing a challenging condition. Unlike standard treatments like pain management, dietary changes, or surgery, miES provides a targeted procedure that directly addresses the potential cause of recurrent pancreatitis. This technique allows for precise intervention during an endoscopic ultrasound, potentially reducing inflammation and preventing future episodes. Additionally, the use of indomethacin during the procedure might help minimize complications, making it a promising option for patients who haven't found relief with traditional methods.
What evidence suggests that ERCP with sphincterotomy is effective for reducing recurrent pancreatitis in patients with pancreas divisum?
Research has shown that a procedure called ERCP with sphincterotomy can help prevent the recurrence of pancreatitis. One study found that 94% of patients who underwent this procedure did not experience another episode over approximately 3.5 years. Another study reported effectiveness in 92.5% of cases, providing long-term relief. In this trial, participants will be randomized to receive either ERCP with minor papilla endoscopic sphincterotomy (miES) or a sham procedure. These findings suggest that ERCP with sphincterotomy could be a viable option for individuals who frequently experience pancreatitis, particularly those with a condition called pancreas divisum. However, limited data currently exist, so further research is necessary.12467
Who Is on the Research Team?
Gregory A Cote, MD, MS
Principal Investigator
Oregon Health and Science University
Are You a Good Fit for This Trial?
This trial is for adults over 18 who've had at least two episodes of acute pancreatitis within the last 24 months, confirmed pancreas divisum, and no clear cause for their condition. They must be able to participate fully in the study and have not undergone any prior minor papilla therapy or regularly used opioids for abdominal pain.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either the ERCP with sphincterotomy procedure or a sham procedure
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ERCP with sphincterotomy
Trial Overview
The study tests if ERCP with sphincterotomy can reduce pancreatitis risk or recurrence in patients with pancreas divisum. Participants are randomly assigned to receive either the actual procedure or a sham (fake) procedure, followed up at intervals until a maximum of 48 months.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Subjects randomized to EUS + ERCP with miES will undergo the procedure at the same time as endoscopic ultrasound (EUS), under sedation. Indomethacin (100 mg) will be administered rectally at the onset of the ERCP procedure in patients with no known allergy to indomethacin. The techniques used to perform the endoscopic retrograde cholangiopancreatography (ERCP)with miES (minor papilla endoscopic sphincterotomy) will be left to the discretion of the study endoscopist. The extent of sphincterotomy will be per the discretion of the treating endoscopist. Unless methylene blue (or similar chromoendoscopy agent such as indigo carmine) has already been used to facilitate minor papilla cannulation, diluted dye will be injected into the duodenum.
Subjects randomized to EUS + sham will undergo a diagnostic endoscopic ultrasound (EUS) under sedation. The physician investigator will not make any attempts to achieve minor papilla cannulation, but photo document the minor papilla using a duodenoscope. Diluted dye will be injected into the duodenum. A small caliber prophylactic pancreatic duct stent will be deposited into the duodenal lumen. These maneuvers are performed to minimize the risk of unmasking.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Gregory A. Cote
Lead Sponsor
Oregon Health and Science University
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Citations
SpHincterotomy for Acute Recurrent Pancreatitis Randomized ...
There are limited preliminary data supporting the use of endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy ( ...
SpHincterotomy for Acute Recurrent Pancreatitis (SHARP)
The purpose of this study is to determine if a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk ...
Determining the Optimal Subgroup of Patients in Whom ...
At the index ERCP of RAP patients without pancreatic duct dilatation, 45.9% of endoscopists might perform biliary sphincterotomy. However, the ...
ERCP and Endoscopic Sphincterotomy (ES): A Safe and ...
Eighty-nine patients were successfully treated with an ERCP alone, and 84 patients (94%) had no recurrence of pancreatitis with a mean follow-up of 41 months (± ...
Idiopathic recurrent pancreatitis: long-term results after ...
Conclusions: Diagnostic and therapeutic ERCP and UDCA were effective in 92.5% of our cases, over a long follow-up, indicating that the term "idiopathic" was ...
Evaluation of Safety and Outcomes of Endoscopic ...
They reported that early complications occurred in 7.8% and late complications developed in 10 out of 110 patients. They concluded that ERCP is safe and ...
Role of endoscopic retrograde cholangiopancreatography in ...
This paper looks at how ERCP is used to treat conditions such as acute gallstone pancreatitis, pancreas divisum (PD), sphincter of Oddi dysfunction (SOD), and ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.